
## Eric Charles LaCasse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8300401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?. Cell Death and Disease, 2020, 11, 350.	6.3	1
2	SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Science Signaling, 2020, 13, .	3.6	34
3	The transcription factor SP3 drives TNF-α expression in response to Smac mimetics. Science Signaling, 2019, 12, .	3.6	9
4	Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells. Molecular and Cellular Oncology, 2019, 6, 1607456.	0.7	3
5	Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy. Skeletal Muscle, 2019, 9, 13.	4.2	24
6	Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression. Molecular Therapy - Oncolytics, 2018, 10, 28-39.	4.4	19
7	Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization. PLoS ONE, 2018, 13, e0193643.	2.5	27
8	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nature Communications, 2017, 8, .	12.8	103
9	How genetic testing can lead to targeted management of XIAP deficiency–related inflammatory bowel disease. Genetics in Medicine, 2017, 19, 133-143.	2.4	26
10	Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Oncotarget, 2017, 8, 3495-3508.	1.8	22
11	Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists. International Journal of Developmental Biology, 2015, 59, 141-147.	0.6	17
12	The inhibitors of apoptosis (IAPs): Over 20 years of research into life and death. Seminars in Cell and Developmental Biology, 2015, 39, 70-71.	5.0	1
13	Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncolmmunology, 2014, 3, e28541.	4.6	12
14	Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis. Frontiers in Immunology, 2014, 5, 34.	4.8	44
15	Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature Biotechnology, 2014, 32, 182-190.	17.5	104
16	Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends in Molecular Medicine, 2014, 20, 652-665.	6.7	96
17	Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Letters, 2013, 332, 215-224.	7.2	41
18	Loss of cIAP1 attenuates soleus muscle pathology and improves diaphragm function in mdx mice. Human Molecular Genetics, 2013, 22, 867-878.	2.9	14

ERIC CHARLES LACASSE

#	Article	IF	CITATIONS
19	Modulation of immune signalling by inhibitors of apoptosis. Trends in Immunology, 2012, 33, 535-545.	6.8	125
20	TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF-κB Signaling Pathway. Science Signaling, 2012, 5, ra75.	3.6	66
21	Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. Journal of Clinical Oncology, 2009, 27, 1660-1666.	1.6	88
22	Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 4741-4746.	1.6	115
23	Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound. Cancer Research, 2009, 69, 7729-7738.	0.9	68
24	Downregulation of XIAP expression in ovarian cancer cells induces cell death <i>in vitro</i> and <i>in vivo</i> . International Journal of Cancer, 2008, 122, 1430-1434.	5.1	50
25	IAP-targeted therapies for cancer. Oncogene, 2008, 27, 6252-6275.	5.9	455
26	X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function. Journal of Immunology, 2007, 179, 7553-7560.	0.8	25
27	The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1543-1568.	4.9	506
28	XIAP Protection of Photoreceptors in Animal Models of Retinitis Pigmentosa. PLoS ONE, 2007, 2, e314.	2.5	73
29	The role of XAF1 in cancer. Current Opinion in Investigational Drugs, 2007, 8, 469-76.	2.3	33
30	X-Linked Inhibitor of Apoptosis Antagonism: Strategies in Cancer Treatment. Clinical Cancer Research, 2006, 12, 3238-3242.	7.0	33
31	Inhibitor of Apoptosis Protein cIAP2 Is Essential for Lipopolysaccharide-Induced Macrophage Survival. Molecular and Cellular Biology, 2006, 26, 699-708.	2.3	182
32	Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. Clinical Cancer Research, 2006, 12, 5231-5241.	7.0	136
33	Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM(R)640. Annals of the New York Academy of Sciences, 2005, 1058, 215-234.	3.8	56
34	ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 37383-37392.	3.4	49
35	Spurious splicing within the XIAP 5' UTR occurs in the Rluc/Fluc but not the Âgal/CAT bicistronic reporter system. Rna, 2005, 11, 1605-1609.	3.5	57
36	Distinct Role of Calmodulin and Calmodulin-dependent Protein Kinase-II in Lipopolysaccharide and Tumor Necrosis Factor-1±-mediated Suppression of Apoptosis and Antiapoptotic c-IAP2 Gene Expression in Human Monocytic Cells*. Journal of Biological Chemistry, 2005, 280, 37536-37546.	3.4	26

ERIC CHARLES LACASSE

#	Article	IF	CITATIONS
37	Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene, 2004, 23, 8105-8117.	5.9	165
38	Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clinical Cancer Research, 2003, 9, 2826-36.	7.0	175
39	Baculoviral IAP Repeat-Containing-4 Protects Optic Nerve Axons in a Rat Glaucoma Model. Molecular Therapy, 2002, 5, 780-787.	8.2	151
40	Evidence for Apoptosis in the Fetal Down Syndrome Brain. Journal of Child Neurology, 2001, 16, 438.	1.4	3
41	Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 1999, 264, 781-788.	2.1	319
42	The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 1998, 17, 3247-3259.	5.9	920
43	Recruitment of Octamer Transcription Factors to DNA by Glucocorticoid Receptor. Molecular and Cellular Biology, 1998, 18, 3416-3430.	2.3	89
44	Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins. Nucleic Acids Research, 1995, 23, 1647-1656.	14.5	211
45	Nuclear and nuclear envelope binding proteins of the glucocorticoid receptor nuclear localization peptide identified by crosslinking. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 279-285.	2.5	8
46	Microsomal dexamethasone binding sites identified by affinity labelling. The Journal of Steroid Biochemistry, 1990, 35, 47-54.	1.1	9